ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Oligonucleotide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
Published Date: June 2025
|
Report Code: QYRE-Auto-26O10944
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Oligonucleotide Therapeutics Sales Market Report 2022
BUY CHAPTERS

Global Oligonucleotide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Code: QYRE-Auto-26O10944
Report
June 2025
Pages:155
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Ionis Pharmaceuticals
Alnylam
Nippon Shinyaku
SOBI
Novartis
BioNTech
Pfizer Inc
Moderna Therapeutics
CureVac
Regulus Therapeutics
ProQR
Secarna
Mina Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

Oligonucleotide Therapeutics Market Size

In 2024, the global market size of Oligonucleotide Therapeutics was estimated to be worth US$ 7536 million and is forecast to reach approximately US$ 9690 million by 2031 with a CAGR of 3.7% during the forecast period 2025-2031.

Oligonucleotide Therapeutics Market

Oligonucleotide Therapeutics Market

Oligonucleotide therapeutics are a class of precision medicines composed of short DNA or RNA sequences designed to specifically target and modulate the expression of genes involved in disease processes. These therapies can act by silencing, inhibiting, or correcting genetic abnormalities at the molecular level, offering a highly targeted approach to treat various conditions such as genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics include antisense oligonucleotides, small interfering RNA (siRNA), and aptamers, and they represent a promising area of drug development due to their ability to address previously untreatable diseases.
Key driver of the oligonucleotide therapeutics market is the growing prevalence of genetic and rare diseases that require precise and targeted treatment options. Advances in genomics and personalized medicine have fueled interest in oligonucleotide therapies, which can directly modulate gene expression and offer solutions for conditions that were previously difficult to treat. The success of approved oligonucleotide drugs, such as antisense oligonucleotides and siRNA therapies, has increased confidence in this field, leading to more investments and research in developing novel treatments for a wide range of diseases, including cancers and neurological disorders.
One significant challenge in the oligonucleotide therapeutics market is the complexity of delivering these molecules effectively to target cells or tissues. Oligonucleotides are large, negatively charged molecules that face hurdles in stability, bioavailability, and efficient cellular uptake. Developing delivery systems that can ensure targeted and sustained delivery while minimizing immune responses or off-target effects remains a critical challenge. Additionally, the high costs associated with research, development, and manufacturing of oligonucleotide-based drugs pose financial challenges, limiting accessibility and widespread adoption, especially in resource-constrained healthcare settings.
Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023. Following Europe, North Americas is the second largest consumption place with the consumption market share of 34.9%. The global key companies of oligonucleotide therapeutics include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 97.87% in terms of revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapeutics.
The Oligonucleotide Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oligonucleotide Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation

Scope of Oligonucleotide Therapeutics Market Report

Report Metric Details
Report Name Oligonucleotide Therapeutics Market
CAGR 3.7%
Segment by Type
  • Antisense Oligonucleotides (ASO)
  • siRNA
  • mRNA
Segment by Application
  • Neuromuscular Diseases
  • hATTR
  • COVID-19
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
  • Chapter 2: Revenue of Oligonucleotide Therapeutics in global and regional level.
  • Chapter 3: Detailed analysis of Oligonucleotide Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotide Therapeutics revenue, gross margin, and recent development, etc.
  • Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: Research Findings and Conclusion

FAQ for this report

What is the Oligonucleotide Therapeutics Market share by region?

Ans: Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023.

What is the market share of major companies in Oligonucleotide Therapeutics Market?

Ans: In 2023, the global top five players had a share approximately 97.87% in terms of revenue.

Who are the main players in the Oligonucleotide Therapeutics Market report?

Ans: The main players in the Oligonucleotide Therapeutics Market are Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna

What are the Application segmentation covered in the Oligonucleotide Therapeutics Market report?

Ans: The Applications covered in the Oligonucleotide Therapeutics Market report are Neuromuscular Diseases, hATTR, COVID-19, Other

What are the Type segmentation covered in the Oligonucleotide Therapeutics Market report?

Ans: The Types covered in the Oligonucleotide Therapeutics Market report are Antisense Oligonucleotides (ASO), siRNA, mRNA

Recommended Reports

Oligonucleotide Therapeutics

Gene & RNA Therapies

RNA Interference

1 Study Coverage
1.1 Oligonucleotide Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Antisense Oligonucleotides (ASO)
1.2.3 siRNA
1.2.4 mRNA
1.3 Market by Application
1.3.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 COVID-19
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oligonucleotide Therapeutics Market Size Estimates and Forecasts
2.2 Oligonucleotide Therapeutics Market Size by Region: 2024 Versus 2031
2.2.1 Global Oligonucleotide Therapeutics Revenue by Region: 2020-2025
2.2.2 Global Oligonucleotide Therapeutics Revenue Forecast by Region (2026-2031)
2.2.3 Global Oligonucleotide Therapeutics Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Oligonucleotide Therapeutics Revenue by Type (2020-2031)
3.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Oligonucleotide Therapeutics Revenue by Application (2020-2031)
3.2.2 Global Oligonucleotide Therapeutics Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Antisense Oligonucleotides (ASO) of Oligonucleotide Therapeutics Revenue Market Share by Application
3.3.2 siRNA of Oligonucleotide Therapeutics Revenue Market Share by Application
3.3.3 mRNA of Oligonucleotide Therapeutics Revenue Market Share by Application
4 Global Oligonucleotide Therapeutics by Company
4.1 Global Oligonucleotide Therapeutics Revenue by Company (2020-2025)
4.2 Global Oligonucleotide Therapeutics Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Oligonucleotide Therapeutics Companies around the World: Ranking by Revenue
4.3.2 Global Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Oligonucleotide Therapeutics Companies Headquarters & Product Type
4.4.1 Global Oligonucleotide Therapeutics Companies Headquarters
4.4.2 Date of International Companies Enter into Oligonucleotide Therapeutics Market
4.4.3 Global Oligonucleotide Therapeutics Companies Product & Service
4.4.4 Antisense Oligonucleotides (ASO) Revenue Market Share of Oligonucleotide Therapeutics by Company
4.4.5 siRNA Revenue Market Share of Oligonucleotide Therapeutics by Company
4.4.6 mRNA Revenue Market Share of Oligonucleotide Therapeutics by Company
4.5 Global Oligonucleotide Therapeutics Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Sarepta Therapeutics
5.1.1 Sarepta Therapeutics Corporation Information
5.1.2 Sarepta Therapeutics Description, Business Overview
5.1.3 Sarepta Therapeutics Oligonucleotide Therapeutics Products Offered
5.1.4 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.1.5 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue by Product in 2024
5.1.6 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue by Application in 2024
5.1.7 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.1.8 Sarepta Therapeutics Recent Developments
5.2 Ionis Pharmaceuticals
5.2.1 Ionis Pharmaceuticals Corporation Information
5.2.2 Ionis Pharmaceuticals Description, Business Overview
5.2.3 Ionis Pharmaceuticals Oligonucleotide Therapeutics Products Offered
5.2.4 Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.2.5 Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue by Product in 2024
5.2.6 Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue by Application in 2024
5.2.7 Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.2.8 Ionis Pharmaceuticals Recent Developments
5.3 Alnylam
5.3.1 Alnylam Corporation Information
5.3.2 Alnylam Description, Business Overview
5.3.3 Alnylam Oligonucleotide Therapeutics Products Offered
5.3.4 Alnylam Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.3.5 Alnylam Oligonucleotide Therapeutics Revenue by Product in 2024
5.3.6 Alnylam Oligonucleotide Therapeutics Revenue by Application in 2024
5.3.7 Alnylam Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.3.8 Alnylam Recent Developments
5.4 Biogen
5.4.1 Biogen Corporation Information
5.4.2 Biogen Description, Business Overview
5.4.3 Biogen Oligonucleotide Therapeutics Products Offered
5.4.4 Biogen Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.4.5 Biogen Oligonucleotide Therapeutics Revenue by Product in 2024
5.4.6 Biogen Oligonucleotide Therapeutics Revenue by Application in 2024
5.4.7 Biogen Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.4.8 Biogen Recent Developments
5.5 Nippon Shinyaku
5.5.1 Nippon Shinyaku Corporation Information
5.5.2 Nippon Shinyaku Description, Business Overview
5.5.3 Nippon Shinyaku Oligonucleotide Therapeutics Products Offered
5.5.4 Nippon Shinyaku Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.5.5 Nippon Shinyaku Oligonucleotide Therapeutics Revenue by Product in 2024
5.5.6 Nippon Shinyaku Oligonucleotide Therapeutics Revenue by Application in 2024
5.5.7 Nippon Shinyaku Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.5.8 Nippon Shinyaku Recent Developments
5.6 Sobi
5.6.1 Sobi Corporation Information
5.6.2 Sobi Description, Business Overview
5.6.3 Sobi Oligonucleotide Therapeutics Products Offered
5.6.4 Sobi Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.6.5 Sobi Oligonucleotide Therapeutics Revenue by Product in 2024
5.6.6 Sobi Oligonucleotide Therapeutics Revenue by Application in 2024
5.6.7 Sobi Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.6.8 Sobi Recent Developments
5.7 Novartis
5.7.1 Novartis Corporation Information
5.7.2 Novartis Description, Business Overview
5.7.3 Novartis Oligonucleotide Therapeutics Products Offered
5.7.4 Novartis Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.7.5 Novartis Oligonucleotide Therapeutics Revenue by Product in 2024
5.7.6 Novartis Oligonucleotide Therapeutics Revenue by Application in 2024
5.7.7 Novartis Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.7.8 Novartis Recent Developments
5.8 BioNTech
5.8.1 BioNTech Corporation Information
5.8.2 BioNTech Description, Business Overview
5.8.3 BioNTech Oligonucleotide Therapeutics Products Offered
5.8.4 BioNTech Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.8.5 BioNTech Oligonucleotide Therapeutics Revenue by Product in 2024
5.8.6 BioNTech Oligonucleotide Therapeutics Revenue by Application in 2024
5.8.7 BioNTech Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.8.8 BioNTech Recent Developments
5.9 Pfizer
5.9.1 Pfizer Corporation Information
5.9.2 Pfizer Description, Business Overview
5.9.3 Pfizer Oligonucleotide Therapeutics Products Offered
5.9.4 Pfizer Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.9.5 Pfizer Oligonucleotide Therapeutics Revenue by Product in 2024
5.9.6 Pfizer Oligonucleotide Therapeutics Revenue by Application in 2024
5.9.7 Pfizer Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.9.8 Pfizer Recent Developments
5.10 Moderna Therapeutics
5.10.1 Moderna Therapeutics Corporation Information
5.10.2 Moderna Therapeutics Description, Business Overview
5.10.3 Moderna Therapeutics Oligonucleotide Therapeutics Products Offered
5.10.4 Moderna Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.10.5 Moderna Therapeutics Oligonucleotide Therapeutics Revenue by Product in 2024
5.10.6 Moderna Therapeutics Oligonucleotide Therapeutics Revenue by Application in 2024
5.10.7 Moderna Therapeutics Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.10.8 Moderna Therapeutics Recent Developments
5.11 Jazz Pharmaceuticals
5.11.1 Jazz Pharmaceuticals Corporation Information
5.11.2 Jazz Pharmaceuticals Description, Business Overview
5.11.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Products Offered
5.11.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.11.5 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue by Product in 2024
5.11.6 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue by Application in 2024
5.11.7 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.11.8 Jazz Pharmaceuticals Recent Developments
5.12 CureVac
5.12.1 CureVac Corporation Information
5.12.2 CureVac Description, Business Overview
5.12.3 CureVac Oligonucleotide Therapeutics Products Offered
5.12.4 CureVac Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.12.5 CureVac Oligonucleotide Therapeutics Revenue by Product in 2024
5.12.6 CureVac Oligonucleotide Therapeutics Revenue by Application in 2024
5.12.7 CureVac Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.12.8 CureVac Recent Developments
5.13 Regulus Therapeutics
5.13.1 Regulus Therapeutics Corporation Information
5.13.2 Regulus Therapeutics Description, Business Overview
5.13.3 Regulus Therapeutics Oligonucleotide Therapeutics Products Offered
5.13.4 Regulus Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.13.5 Regulus Therapeutics Oligonucleotide Therapeutics Revenue by Product in 2024
5.13.6 Regulus Therapeutics Oligonucleotide Therapeutics Revenue by Application in 2024
5.13.7 Regulus Therapeutics Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.13.8 Regulus Therapeutics Recent Developments
5.14 ProQR
5.14.1 ProQR Corporation Information
5.14.2 ProQR Description, Business Overview
5.14.3 ProQR Oligonucleotide Therapeutics Products Offered
5.14.4 ProQR Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.14.5 ProQR Oligonucleotide Therapeutics Revenue by Product in 2024
5.14.6 ProQR Oligonucleotide Therapeutics Revenue by Application in 2024
5.14.7 ProQR Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.14.8 ProQR Recent Developments
5.15 Secarna
5.15.1 Secarna Corporation Information
5.15.2 Secarna Description, Business Overview
5.15.3 Secarna Oligonucleotide Therapeutics Products Offered
5.15.4 Secarna Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.15.5 Secarna Oligonucleotide Therapeutics Revenue by Product in 2024
5.15.6 Secarna Oligonucleotide Therapeutics Revenue by Application in 2024
5.15.7 Secarna Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.15.8 Secarna Recent Developments
5.16 MiNA Therapeutics
5.16.1 MiNA Therapeutics Corporation Information
5.16.2 MiNA Therapeutics Description, Business Overview
5.16.3 MiNA Therapeutics Oligonucleotide Therapeutics Products Offered
5.16.4 MiNA Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.16.5 MiNA Therapeutics Oligonucleotide Therapeutics Revenue by Product in 2024
5.16.6 MiNA Therapeutics Oligonucleotide Therapeutics Revenue by Application in 2024
5.16.7 MiNA Therapeutics Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.16.8 MiNA Therapeutics Recent Developments
5.17 Sylentis
5.17.1 Sylentis Corporation Information
5.17.2 Sylentis Description, Business Overview
5.17.3 Sylentis Oligonucleotide Therapeutics Products Offered
5.17.4 Sylentis Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.17.5 Sylentis Oligonucleotide Therapeutics Revenue by Product in 2024
5.17.6 Sylentis Oligonucleotide Therapeutics Revenue by Application in 2024
5.17.7 Sylentis Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.17.8 Sylentis Recent Developments
5.18 Arrowhead
5.18.1 Arrowhead Corporation Information
5.18.2 Arrowhead Description, Business Overview
5.18.3 Arrowhead Oligonucleotide Therapeutics Products Offered
5.18.4 Arrowhead Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.18.5 Arrowhead Oligonucleotide Therapeutics Revenue by Product in 2024
5.18.6 Arrowhead Oligonucleotide Therapeutics Revenue by Application in 2024
5.18.7 Arrowhead Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.18.8 Arrowhead Recent Developments
5.19 Silence Therapeutics
5.19.1 Silence Therapeutics Corporation Information
5.19.2 Silence Therapeutics Description, Business Overview
5.19.3 Silence Therapeutics Oligonucleotide Therapeutics Products Offered
5.19.4 Silence Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.19.5 Silence Therapeutics Oligonucleotide Therapeutics Revenue by Product in 2024
5.19.6 Silence Therapeutics Oligonucleotide Therapeutics Revenue by Application in 2024
5.19.7 Silence Therapeutics Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.19.8 Silence Therapeutics Recent Developments
5.20 Dicerna
5.20.1 Dicerna Corporation Information
5.20.2 Dicerna Description, Business Overview
5.20.3 Dicerna Oligonucleotide Therapeutics Products Offered
5.20.4 Dicerna Oligonucleotide Therapeutics Revenue and Gross Margin (2020-2025)
5.20.5 Dicerna Oligonucleotide Therapeutics Revenue by Product in 2024
5.20.6 Dicerna Oligonucleotide Therapeutics Revenue by Application in 2024
5.20.7 Dicerna Oligonucleotide Therapeutics Revenue by Geographic Area in 2024
5.20.8 Dicerna Recent Developments
6 North America
6.1 North America Oligonucleotide Therapeutics Market Size YoY Growth 2020-2031
6.2 North America Oligonucleotide Therapeutics Market Facts & Figures by Country (2020-2031)
6.3 North America Oligonucleotide Therapeutics Revenue by Type (2020-2025)
6.4 North America Oligonucleotide Therapeutics Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Oligonucleotide Therapeutics Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Oligonucleotide Therapeutics Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Oligonucleotide Therapeutics Revenue by Type (2020-2025)
7.4 Asia-Pacific Oligonucleotide Therapeutics Revenue by Application (2020-2025)
8 Europe
8.1 Europe Oligonucleotide Therapeutics Market Size YoY Growth 2020-2031
8.2 Europe Oligonucleotide Therapeutics Market Facts & Figures by Country (2020-2031)
8.3 Europe Oligonucleotide Therapeutics Revenue by Type (2020-2025)
8.4 Europe Oligonucleotide Therapeutics Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Oligonucleotide Therapeutics Market Size YoY Growth 2020-2031
9.2 Latin America Oligonucleotide Therapeutics Market Facts & Figures by Country (2020-2031)
9.3 Latin America Oligonucleotide Therapeutics Revenue by Type (2020-2025)
9.4 Latin America Oligonucleotide Therapeutics Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Oligonucleotide Therapeutics Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Oligonucleotide Therapeutics Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Oligonucleotide Therapeutics Revenue by Type (2020-2025)
10.4 Middle East and Africa Oligonucleotide Therapeutics Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Oligonucleotide Therapeutics Supply Chain Analysis
11.2 Oligonucleotide Therapeutics Key Raw Materials and Upstream Suppliers
11.3 Oligonucleotide Therapeutics Clients Analysis
11.4 Oligonucleotide Therapeutics Sales Channel and Sales Model Analysis
11.4.1 Oligonucleotide Therapeutics Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Oligonucleotide Therapeutics Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Oligonucleotide Therapeutics Distributors
12 Oligonucleotide Therapeutics Market Dynamics
12.1 Oligonucleotide Therapeutics Industry Trends
12.2 Oligonucleotide Therapeutics Market Drivers
12.3 Oligonucleotide Therapeutics Market Challenges
12.4 Oligonucleotide Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
FEATURED COMPANIES
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Ionis Pharmaceuticals
Alnylam
Nippon Shinyaku
SOBI
Novartis
BioNTech
Pfizer Inc
Moderna Therapeutics
CureVac
Regulus Therapeutics
ProQR
Secarna
Mina Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
List of Tables
 Table 1. Global Oligonucleotide Therapeutics Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Global Oligonucleotide Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 3. Global Oligonucleotide Therapeutics Market Size by Region (US$ Million): 2024 VS 2031
 Table 4. Global Oligonucleotide Therapeutics Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Oligonucleotide Therapeutics Revenue Forecast by Region (2026-2031) & (US$ Million)
 Table 6. Global Oligonucleotide Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 7. Global Oligonucleotide Therapeutics Revenue Forecast by Type (2026-2031) & (US$ Million)
 Table 8. Global Oligonucleotide Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 9. Global Oligonucleotide Therapeutics Revenue Forecast by Application (2026-2031) & (US$ Million)
 Table 10. Oligonucleotide Therapeutics Revenue by Company (2020-2025) & (US$ Million)
 Table 11. Oligonucleotide Therapeutics Revenue Share by Company (2020-2025)
 Table 12. Ranking of Global Top Oligonucleotide Therapeutics Players by Revenue (US$ Million) in 2024
 Table 13. Global Oligonucleotide Therapeutics Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
 Table 14. Global Oligonucleotide Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapeutics as of 2024)
 Table 15. Global Oligonucleotide Therapeutics Companies Headquarters
 Table 16. Date of International Companies Enter into Oligonucleotide Therapeutics Market
 Table 17. Global Oligonucleotide Therapeutics Companies Product & Service
 Table 18. Global Oligonucleotide Therapeutics Mergers & Acquisitions, Expansion Plans
 Table 19. Sarepta Therapeutics Corporation Information
 Table 20. Sarepta Therapeutics Description and Business Overview
 Table 21. Sarepta Therapeutics Oligonucleotide Therapeutics Product
 Table 22. Sarepta Therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 23. Sarepta Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 24. Sarepta Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 25. Sarepta Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 26. Sarepta Therapeutics Recent Developments
 Table 27. Ionis Pharmaceuticals Corporation Information
 Table 28. Ionis Pharmaceuticals Description and Business Overview
 Table 29. Ionis Pharmaceuticals Oligonucleotide Therapeutics Product
 Table 30. Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 31. Ionis Pharmaceuticals Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 32. Ionis Pharmaceuticals Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 33. Ionis Pharmaceuticals Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 34. Ionis Pharmaceuticals Recent Developments
 Table 35. Alnylam Corporation Information
 Table 36. Alnylam Description and Business Overview
 Table 37. Alnylam Oligonucleotide Therapeutics Product
 Table 38. Alnylam Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 39. Alnylam Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 40. Alnylam Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 41. Alnylam Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 42. Alnylam Recent Developments
 Table 43. Biogen Corporation Information
 Table 44. Biogen Description and Business Overview
 Table 45. Biogen Oligonucleotide Therapeutics Product
 Table 46. Biogen Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Biogen Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 48. Biogen Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 49. Biogen Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 50. Biogen Recent Developments
 Table 51. Nippon Shinyaku Corporation Information
 Table 52. Nippon Shinyaku Description and Business Overview
 Table 53. Nippon Shinyaku Oligonucleotide Therapeutics Product
 Table 54. Nippon Shinyaku Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 55. Nippon Shinyaku Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 56. Nippon Shinyaku Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 57. Nippon Shinyaku Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 58. Nippon Shinyaku Recent Developments
 Table 59. Sobi Corporation Information
 Table 60. Sobi Description and Business Overview
 Table 61. Sobi Oligonucleotide Therapeutics Product
 Table 62. Sobi Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 63. Sobi Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 64. Sobi Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 65. Sobi Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 66. Sobi Recent Developments
 Table 67. Novartis Corporation Information
 Table 68. Novartis Description and Business Overview
 Table 69. Novartis Oligonucleotide Therapeutics Product
 Table 70. Novartis Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 71. Novartis Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 72. Novartis Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 73. Novartis Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 74. Novartis Recent Developments
 Table 75. BioNTech Corporation Information
 Table 76. BioNTech Description and Business Overview
 Table 77. BioNTech Oligonucleotide Therapeutics Product
 Table 78. BioNTech Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 79. BioNTech Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 80. BioNTech Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 81. BioNTech Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 82. BioNTech Recent Developments
 Table 83. Pfizer Corporation Information
 Table 84. Pfizer Description and Business Overview
 Table 85. Pfizer Oligonucleotide Therapeutics Product
 Table 86. Pfizer Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 87. Pfizer Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 88. Pfizer Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 89. Pfizer Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 90. Pfizer Recent Developments
 Table 91. Moderna Therapeutics Corporation Information
 Table 92. Moderna Therapeutics Description and Business Overview
 Table 93. Moderna Therapeutics Oligonucleotide Therapeutics Product
 Table 94. Moderna Therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 95. Moderna Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 96. Moderna Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 97. Moderna Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 98. Moderna Therapeutics Recent Developments
 Table 99. Jazz Pharmaceuticals Corporation Information
 Table 100. Jazz Pharmaceuticals Description and Business Overview
 Table 101. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product
 Table 102. Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Jazz Pharmaceuticals Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 104. Jazz Pharmaceuticals Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 105. Jazz Pharmaceuticals Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 106. Jazz Pharmaceuticals Recent Developments
 Table 107. CureVac Corporation Information
 Table 108. CureVac Description and Business Overview
 Table 109. CureVac Oligonucleotide Therapeutics Product
 Table 110. CureVac Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 111. CureVac Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 112. CureVac Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 113. CureVac Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 114. CureVac Recent Developments
 Table 115. Regulus Therapeutics Corporation Information
 Table 116. Regulus Therapeutics Description and Business Overview
 Table 117. Regulus Therapeutics Oligonucleotide Therapeutics Product
 Table 118. Regulus Therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 119. Regulus Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 120. Regulus Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 121. Regulus Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 122. Regulus Therapeutics Recent Developments
 Table 123. ProQR Corporation Information
 Table 124. ProQR Description and Business Overview
 Table 125. ProQR Oligonucleotide Therapeutics Product
 Table 126. ProQR Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 127. ProQR Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 128. ProQR Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 129. ProQR Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 130. ProQR Recent Developments
 Table 131. Secarna Corporation Information
 Table 132. Secarna Description and Business Overview
 Table 133. Secarna Oligonucleotide Therapeutics Product
 Table 134. Secarna Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 135. Secarna Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 136. Secarna Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 137. Secarna Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 138. Secarna Recent Developments
 Table 139. MiNA Therapeutics Corporation Information
 Table 140. MiNA Therapeutics Description and Business Overview
 Table 141. MiNA Therapeutics Oligonucleotide Therapeutics Product
 Table 142. MiNA Therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 143. MiNA Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 144. MiNA Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 145. MiNA Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 146. MiNA Therapeutics Recent Developments
 Table 147. Sylentis Corporation Information
 Table 148. Sylentis Description and Business Overview
 Table 149. Sylentis Oligonucleotide Therapeutics Product
 Table 150. Sylentis Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 151. Sylentis Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 152. Sylentis Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 153. Sylentis Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 154. Sylentis Recent Developments
 Table 155. Arrowhead Corporation Information
 Table 156. Arrowhead Description and Business Overview
 Table 157. Arrowhead Oligonucleotide Therapeutics Product
 Table 158. Arrowhead Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 159. Arrowhead Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 160. Arrowhead Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 161. Arrowhead Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 162. Arrowhead Recent Developments
 Table 163. Silence Therapeutics Corporation Information
 Table 164. Silence Therapeutics Description and Business Overview
 Table 165. Silence Therapeutics Oligonucleotide Therapeutics Product
 Table 166. Silence Therapeutics Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 167. Silence Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 168. Silence Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 169. Silence Therapeutics Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 170. Silence Therapeutics Recent Developments
 Table 171. Dicerna Corporation Information
 Table 172. Dicerna Description and Business Overview
 Table 173. Dicerna Oligonucleotide Therapeutics Product
 Table 174. Dicerna Oligonucleotide Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 175. Dicerna Revenue Proportion of Oligonucleotide Therapeutics by Product in 2024
 Table 176. Dicerna Revenue Proportion of Oligonucleotide Therapeutics by Application in 2024
 Table 177. Dicerna Revenue Proportion of Oligonucleotide Therapeutics by Geographic Area in 2024
 Table 178. Dicerna Recent Developments
 Table 179. North America Oligonucleotide Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 180. North America Oligonucleotide Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 181. North America Oligonucleotide Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 182. North America Oligonucleotide Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 183. Asia-Pacific Oligonucleotide Therapeutics Revenue by Region (2020-2025) & (US$ Million)
 Table 184. Asia-Pacific Oligonucleotide Therapeutics Revenue by Region (2026-2031) & (US$ Million)
 Table 185. Asia-Pacific Oligonucleotide Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 186. Asia-Pacific Oligonucleotide Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 187. Europe Oligonucleotide Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 188. Europe Oligonucleotide Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 189. Europe Oligonucleotide Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 190. Europe Oligonucleotide Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 191. Latin America Oligonucleotide Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 192. Latin America Oligonucleotide Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 193. Latin America Oligonucleotide Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 194. Latin America Oligonucleotide Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 195. Middle East and Africa Oligonucleotide Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 196. Middle East and Africa Oligonucleotide Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 197. Middle East and Africa Oligonucleotide Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 198. Middle East and Africa Oligonucleotide Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 199. Oligonucleotide Therapeutics Key Raw Materials, Industry Status and Trend
 Table 200. Oligonucleotide Therapeutics Key Raw Materials and Upstream Suppliers
 Table 201. Oligonucleotide Therapeutics Clients Status and Trend
 Table 202. Oligonucleotide Therapeutics Typical Clients
 Table 203. Oligonucleotide Therapeutics Distributors
 Table 204. Oligonucleotide Therapeutics Market Trends
 Table 205. Oligonucleotide Therapeutics Market Drivers
 Table 206. Oligonucleotide Therapeutics Market Challenges
 Table 207. Oligonucleotide Therapeutics Market Restraints
 Table 208. Research Programs/Design for This Report
 Table 209. Key Data Information from Secondary Sources
 Table 210. Key Data Information from Primary Sources


List of Figures
 Figure 1. Oligonucleotide Therapeutics Product Picture
 Figure 2. Global Oligonucleotide Therapeutics Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
 Figure 3. Global Oligonucleotide Therapeutics Revenue Market Share by Type in 2024 & 2031
 Figure 4. Antisense Oligonucleotides (ASO) Product Picture
 Figure 5. siRNA Product Picture
 Figure 6. mRNA Product Picture
 Figure 7. Global Oligonucleotide Therapeutics Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
 Figure 8. Global Oligonucleotide Therapeutics Revenue Market Share by Application in 2024 & 2031
 Figure 9. Neuromuscular Diseases
 Figure 10. hATTR
 Figure 11. COVID-19
 Figure 12. Other
 Figure 13. Oligonucleotide Therapeutics Report Years Considered
 Figure 14. Global Oligonucleotide Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Oligonucleotide Therapeutics Market Size (2020-2031) & (US$ Million)
 Figure 16. Global Oligonucleotide Therapeutics Market Size Market Share by Region: 2024 Versus 2031
 Figure 17. Global Oligonucleotide Therapeutics Revenue Market Share by Region (2020-2031)
 Figure 18. Global Oligonucleotide Therapeutics Revenue Market Share Forecast by Type (2020-2031)
 Figure 19. Global Oligonucleotide Therapeutics Revenue Market Share Forecast by Application (2020-2031)
 Figure 20. Antisense Oligonucleotides (ASO) of Oligonucleotide Therapeutics Revenue Market Share by Application, 2024 VS 2031
 Figure 21. siRNA of Oligonucleotide Therapeutics Revenue Market Share by Application, 2024 VS 2031
 Figure 22. mRNA of Oligonucleotide Therapeutics Revenue Market Share by Application, 2024 VS 2031
 Figure 23. Oligonucleotide Therapeutics Revenue Share by Company (2024)
 Figure 24. Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 25. Antisense Oligonucleotides (ASO) Revenue Proportion by Company in 2024
 Figure 26. siRNA Revenue Proportion by Company in 2024
 Figure 27. mRNA Revenue Proportion by Company in 2024
 Figure 28. North America Oligonucleotide Therapeutics Revenue 2020-2031 (US$ Million)
 Figure 29. North America Oligonucleotide Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 30. North America Oligonucleotide Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 31. Asia-Pacific Oligonucleotide Therapeutics Revenue 2020-2031 (US$ Million)
 Figure 32. Asia-Pacific Oligonucleotide Therapeutics Revenue Market Share by Region (2020-2031)
 Figure 33. Asia-Pacific Oligonucleotide Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 34. Asia-Pacific Oligonucleotide Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 35. Europe Oligonucleotide Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 36. Europe Oligonucleotide Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 37. Europe Oligonucleotide Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 38. Europe Oligonucleotide Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 39. Latin America Oligonucleotide Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 40. Latin America Oligonucleotide Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 41. Latin America Oligonucleotide Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 42. Latin America Oligonucleotide Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 43. Middle East and Africa Oligonucleotide Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 44. Middle East and Africa Oligonucleotide Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 45. Middle East and Africa Oligonucleotide Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 46. Middle East and Africa Oligonucleotide Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 47. Oligonucleotide Therapeutics Supply Chain (Upstream and Downstream Market)
 Figure 48. Global Production Market Share of Oligonucleotide Therapeutics Raw Materials by Region in 2024
 Figure 49. Oligonucleotide Therapeutics Distribution Channels
 Figure 50. Global Oligonucleotide Therapeutics Percentage 2020-2031: Indirect Sales VS Direct Sales
 Figure 51. Global Oligonucleotide Therapeutics Percentage 2020-2031: Online Sales VS Offline Sales
 Figure 52. Bottom-up and Top-down Approaches for This Report
 Figure 53. Data Triangulation
 Figure 54. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$5900

This license allows only one user to access the PDF.
Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Oligonucleotide Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oligonucleotide Oligo Drugs Market Research Report 2024
Global Oligonucleotide based Therapy Medicinal Product Market Research Report 2024
Global Oligonucleotide Therapy based Drug Market Research Report 2024
Antisense and RNAi Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oligonucleotide Drug Delivery Market Research Report 2024
Global Peptide and Oligonucleotide Drugs Market Research Report 2024
Oligonucleotide Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Oligonucleotide based Therapies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global CNS Specific Antisense Oligonucleotides Market Research Report 2024
Global Nucleic Acid Drugs Market Research Report 2025
Global Oligonucleotide Drugs ONs Market Research Report 2025
Global Antisense Oligonucleotides ASO Therapy Market Research Report 2024
Global Oligonucleotide Market Research Report 2025
Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024
Global Antisense Oligonucleotides based Therapeutics Market Research Report 2024
Antisense and RNAi Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global RNA Interference RNAi Based Therapeutics Market Research Report 2024
Global RNAi Therapeutics Market Research Report 2024
Global RNA Therapeutics Market Research Report 2024

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions